Where Cue Biopharma Stands With Analysts
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish and somewhat bullish ratings for Cue Biopharma (NASDAQ:CUE) in the last quarter, with an average 12-month price target of $10.25, up 13.89% from the previous average of $9.00.
June 15, 2023 | 9:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cue Biopharma has received bullish and somewhat bullish ratings from analysts, with an average 12-month price target of $10.25, a 13.89% increase from the previous average.
The article states that analysts have provided bullish and somewhat bullish ratings for Cue Biopharma in the last quarter. The average 12-month price target has increased by 13.89% from the previous average, indicating a positive outlook for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100